Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Frishman, C. Ram, F. Mcmahon, S. Chrysant, A. Graff, J. Kupiec, H. Hsu (1995)
Comparison of Amlodipine and Benazepril Monotherapy to Amlodipine Plus Benazepril In Patients with Systemic Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group StudyThe Journal of Clinical Pharmacology, 35
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension, 42 6
D. Hilleman, Antonio Reyes, R. Wurdeman, M. Faulkner (2001)
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertensionJournal of Human Hypertension, 15
K. Jamerson, G. Bakris, C. Wun, B. Dahlöf, M. Lefkowitz, S. Manfreda, B. Pitt, E. Velazquez, M. Weber (2004)
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.American journal of hypertension, 17 9
C. Cuspidi, M. Muiesan, L. Valagussa, M. Salvetti, Carlo Biagio, E. Agabiti-Rosei, B. Magnani, A. Zanchetti, Catch Investigators (2002)
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) studyJournal of Hypertension, 20
R. Devereux, B. Dahlöf, E. Gerdts, K. Boman, M. Nieminen, V. Papademetriou, J. Rokkedal, K. Harris, J. Edelman, K. Wachtell (2004)
Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) TrialCirculation, 110
S. Sapienza, P. Sacco, K. Floyd, J. Dicesare, Quynhchau Doan (2003)
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.Clinical therapeutics, 25 6
G. Bakris, M. Weir (2003)
Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed‐Dose Combination ApproachesThe Journal of Clinical Hypertension, 5
L. Hansson, T. Hedner, P. Lund-johansen, S. Kjeldsen, L. Lindholm, J. Syvertsen, J. Lanke, U. Faire, B. Dahlöf, B. Karlberg (2000)
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) studyThe Lancet, 356
J. Neutel, E. Saunders, G. Bakris, W. Cushman, K. Ferdinand, E. Ofili, J. Sowers, M. Weber (2005)
The Efficacy and Safety of Low‐ and High‐ Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE TrialThe Journal of Clinical Hypertension, 7
G. Mancia, G. Backer, A. Dominiczak, R. Cífková, R. Fagard, G. Germano, G. Grassi, A. Heagerty, S. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R. Schmieder, H. Boudier, A. Zanchetti (2007)
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Journal of Hypertension, 25
T. Ogihara, M. Matsuzaki, H. Matsuoka, K. Shimamoto, K. Shimada, H. Rakugi, S. Umemoto, A. Kamiya, N. Suzuki, H. Kumagai, Y. Ohashi, S. Takishita, K. Abe, T. Saruta (2005)
The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial: Rationale and DesignHypertension Research, 28
W.H. Frishman, C.V. Ram, F.G. McMahon (1995)
Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study GroupJ Clin Pharmacol, 35
Morris Brown, C. Palmer, A. Castaigne, P. Leeuw, G. Mancia, T. Rosenthal, L. Ruilope (2000)
Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)The Lancet, 356
T. Rosenthal, I. Gavras (2006)
Fixed-drug combinations as first-line treatment for hypertension.Progress in cardiovascular diseases, 48 6
M. Klag, P. Whelton, Bryan Randall, J. Neaton, F. Brancati, C. Ford, N. Shulman, J. Stamler (1996)
Blood pressure and end-stage renal disease in men.The New England journal of medicine, 334 1
D. Duprez (2004)
Angiotensin II, platelets and oxidative stress.Journal of hypertension, 22 6
Trefor Morgan, A. Anderson (2002)
A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension.American journal of hypertension, 15 6
D. Aguilar, S.D. Solomon (2006)
ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging themeDrugs, 66
P. Bramlage, D. Pittrow, W. Kirch (2004)
The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary careCurrent Medical Research and Opinion, 20
M. Weir (2005)
The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease.American journal of hypertension, 18 4 Pt 2
B. Brenner, M. Cooper, D. Zeeuw, W. Keane, W. Mitch, H. Parving, G. Remuzzi, S. Snapinn, Zhonxin Zhang, S. Shahinfar (2001)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.The New England journal of medicine, 345 12
S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, 342 3
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsThe Lancet, 356
A. Rubio-Guerra, Carlos Treviño-Gomezharper, L. Rodríguez-López, G. Vargas-Ayala, J. Lozano-Nuevo, Adalberto Arceo-Navarro (2002)
Renoprotective Effects of the Combination Trandolapril/Verapamil in Patients with Type 2 Diabetes Mellitus and HypertensionClinical Drug Investigation, 22
S. Turner, E. Boerwinkle (2000)
Genetics of hypertension, target-organ complications, and response to therapy.Circulation, 102 20 Suppl 4
O. Kohlmann, W. Oigman, D. Mion, João Rocha, M. Gomes, Natalino Salgado, G. Feitosa, Ernesto Dallaverde, Artur Ribeiro (2006)
Estudo "LOTHAR": avaliação de eficácia e tolerabilidade da combinação fixa de anlodipino e losartana no tratamento da hipertensão arterial primáriaArquivos Brasileiros De Cardiologia, 86
S. Lewington, R. Clarke, N. Qizilbash, R. Peto, R. Collins (2002)
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 360
W. Cushman, W. Brady, L. Gazdick, R. Zeldin (2002)
The Effect of a Losartan‐Based Treatment Regimen on Isolated Systolic HypertensionThe Journal of Clinical Hypertension, 4
C. Sierra, A. Sierra (2005)
Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockersCurrent Opinion in Nephrology and Hypertension, 14
J. Hosie, I. Wiklund (1995)
Managing hypertension in general practice: can we do better?Journal of human hypertension, 9 Suppl 2
K. Jamerson, O. Nwose, L. Jean-Louis, Lesley Schofield, D. Purkayastha, M. Baron (2004)
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.American journal of hypertension, 17 6
N. Brown, W. Ray, M. Snowden, M. Griffin (1996)
Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedemaClinical Pharmacology & Therapeutics, 60
M. Radomski, R. Palmer, S. Moncada (1987)
The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxideBritish Journal of Pharmacology, 92
E. Lewis, L. Hunsicker, W. Clarke, T. Berl, M. Pohl, J. Lewis, E. Ritz, R. Atkins, R. Rohde, I. Raz (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.The New England journal of medicine, 345 12
R. Fogari, L. Corea, O. Cardoni, F. Cosmi, C. Porcellati, P. Innocenti, M. Provvidenza, M. Timio, M. Bentivoglio, F. Bertocchi, A. Zoppi (1997)
Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone.Journal of cardiovascular pharmacology, 30 4
W. Frishman, B. Bryzinski, L. Coulson, V. DeQuattro, N. Vlachakis, W. Mroczek, G. Dukart, J. Goldberg, D. Alemayehu, K. Koury (1994)
A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide.Archives of internal medicine, 154 13
L. Wing, C. Reid, P. Ryan, L. Beilin, M. Brown, G. Jennings, C. Johnston, J. McNeil, G. Macdonald, J. Marley, Trefor Morgan, M. West (2003)
A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.The New England journal of medicine, 348 7
W. Cushman, D. Reda, H. Perry, David Williams, M. Abdellatif, B. Materson (2000)
Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.Archives of internal medicine, 160 6
W. Cushman, C. Ford, J. Cutler, K. Margolis, B. Davis, R. Grimm, H. Black, B. Hamilton, J. Holland, C. Nwachuku, V. Papademetriou, J. Probstfield, J. Wright, M. Alderman, R. Weiss, L. Piller, Judy Bettencourt, Sandra Walsh (2002)
Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)The Journal of Clinical Hypertension, 4
H. Parving, Hendrik Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Andersen, P. Arner (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.The New England journal of medicine, 345 12
J. Basile (2007)
Fixed-dose combination therapy in the treatment of hypertension: ready for prime time.Southern medical journal, 100 4
Y. Lacourciére, R. Tytus, D. O’Keefe, J. Lenis, R. Orchard, K. Martin (2001)
Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapyJournal of Human Hypertension, 15
K. Malmqvist, T. Kahan, M. Edner, C. Held, A. Hägg, L. Lind, R. Müller-Brunotte, F. Nyström, K. Öhman, M. Osbakken, J. Östergren (2001)
Regression of left ventricular hypertrophy in human hypertension with irbesartanJournal of Hypertension, 19
P. Pablos-Velasco, F. Toral, Juan Esmatjes, F. Fernández-Vega, Martín Torre, A. Pozuelo, L. Ruilope (2002)
Losartan titration versus diuretic combination in type 2 diabetic patientsJournal of Hypertension, 20
E. Ofili, K. Ferdinand, E. Saunders, J. Neutel, G. Bakris, W. Cushman, J. Sowers, M. Weber (2006)
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.Journal of the National Medical Association, 98 4
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA, 289 19
U. Derici, S. Sindel, T. Arınsoy, M. Bali, B. Goker, M. Cemri, E. Hasanoǧlu (2003)
Effects of verapamil slow release plus trandolapril combination therapy on essential hypertension.Current therapeutic research, clinical and experimental, 64 1
Katharina Wolf-Maier, R. Cooper, J. Banegas, S. Giampaoli, H. Hense, M. Joffres, M. Kastarinen, N. Poulter, P. Primatesta, F. Rodríguez‐Artalejo, B. Stegmayr, M. Thamm, J. Tuomilehto, D. Vanuzzo, F. Vescio (2003)
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States.JAMA, 289 18
L. Hansson, L. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, K. Luomanmäki, B. Dahlöf, U. Faire, C. Mörlin, B. Karlberg, P-O Wester, Jan-Erik Björck (1999)
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialThe Lancet, 353
E. Kuschnir, E. Acuña, D. Sevilla, J. Vásquez, M. Bendersky, J. Resk, R. Glazer (1996)
Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo.Clinical therapeutics, 18 6
C. Mogensen, G. Viberti, S. Halimi, E. Ritz, L. Ruilope, G. Jermendy, J. Widimský, P. Sareli, J. Tatoň, J. Rull, G. Erdogan, P. Leeuw, A. Ribeiro, R. Sanchez, R. Mechmeche, J. Nolan, J. Sirotiaková, A. Hamani, A. Scheen, B. Hess, A. Luger, Stephen Thomas (2003)
Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in Albuminuria Regression: PREMIERHypertension: Journal of the American Heart Association, 41
R. Dubey, E. Jackson, T. Lüscher (1995)
Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors.The Journal of clinical investigation, 96 1
S. Yusuf, P. Sleight, J. Pogue (2000)
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med, 342
D. Acanfora, D. Lowenthal, G. Furgi, L. Trojano, C. Picone, G. Iannuzzi, A. Papa, F. Rengo (1997)
THE EFFECTS OF DELAPRIL IN COMBINATION WITH INDAPAMIDE ON GLOMERULAR FILTRATION RATE IN ELDERLY HYPERTENSIVE PATIENTSAmerican Journal of Therapeutics, 4
R. Ames (1998)
Hyperlipidemia of diuretic therapy.Archives des maladies du coeur et des vaisseaux, 91 Suppl
B. Maharaj, K. Byl (1993)
Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients.Journal of human hypertension, 7 5
E. Saunders, M. Weir, B. Kong, J. Hollifield, James Gray, V. Vertes, J. Sowers, M. Zemel, C. Curry, J. Schoenberger, J. Wright, W. Kirkendall, E. Conradi, P. Jenkins, B. McLean, B. Massie, G. Berenson, W. Flamenbaum (1990)
A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks.Archives of internal medicine, 150 8
S. Halimi (2005)
Prévention primaire cardio-rénale chez le diabétique de type 2Presse Medicale, 34
O. Kohlmann, W. Oigman, D. Mion (2006)
The ‘LOTHAR’ study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension [in Portuguese]Arq Bras Cardiol, 86
H. Black, W. Elliott, G. Grandits, P. Grambsch, T. Lucente, W. White, J. Neaton, R. Grimm, L. Hansson, Y. Lacourciére, J. Muller, P. Sleight, M. Weber, G. Williams, J. Wittes, A. Zanchetti, R. Anders (2003)
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.JAMA, 289 16
E. Imai, S. Ito, M. Haneda, J. Chan, H. Makino (2006)
Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): Rationale and Study DesignHypertension Research, 29
K. Nakazono, N. Watanabe, K. Matsuno, J. Sasaki, Tatsuo Sato, M. Inoue (1991)
Does superoxide underlie the pathogenesis of hypertension?Proceedings of the National Academy of Sciences of the United States of America, 88 22
J. Neutel, David Smith, M. Weber (2004)
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.American journal of hypertension, 17 1
L. Hansson, L. Lindholm, T. Ekbom, B. Dahlöf, J. Lanke, B. Scherstén, P. Wester, T. Hedner, U. Faire (1999)
Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 studyThe Lancet, 354
Malcolm Law, N. Wald, Joan Morris, Rachel Jordan (2003)
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ : British Medical Journal, 326
R. Vasan, M. Larson, E. Leip, J. Evans, C. O’Donnell, W. Kannel, D. Levy (2001)
Impact of High-Normal Blood Pressure on the Risk of Cardiovascular DiseaseThe New England Journal of Medicine, 345
M. Maxwell, B. Garrett, E. Saunders, H. Schnaper (1987)
Postmarketing survey of the effects of an atenolol/chlorthalidone combination in the treatment of hypertension.Clinical therapeutics, 9 4
B. Dahlöf, P. Sever, N. Poulter, H. Wedel, D. Beevers, M. Caulfield, R. Collins, S. Kjeldsen, A. Kristinsson, G. Mcinnes, J. Mehlsen, M. Nieminen, E. O’Brien, J. Östergren (2005)
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled triThe Lancet, 366
P. Thürmann (1999)
Angiotensin II Antagonism and the Heart: Valsartan in Left Ventricular HypertrophyCardiology, 91
P. Sever (2006)
New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension SocietyJournal of the Renin-Angiotensin-Aldosterone System, 7
K. Fox (2003)
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)The Lancet, 362
G. Bakris, Mark Williams, L. Dworkin, W. Elliott, Murray Epstein, R. Toto, K. Tuttle, J. Douglas, Willa Hsueh, J. Sowers (2000)
Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, 36 3
James Young, M. Dunlap, M. Pfeffer, J. Probstfield, A. Cohen-Solal, R. Dietz, C. Granger, J. Hradec, J. Kuch, R. McKelvie, J. McMurray, E. Michelson, B. Olofsson, J. Ostergren, P. Held, S. Solomon, S. Yusuf, K. Swedberg (2004)
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction TrialsCirculation, 110
R. Cooper, C. Rotimi (1997)
Hypertension in blacks.American journal of hypertension, 10 7 Pt 1
(2002)
Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trialJ Hypertens, 20
Hussam Abuissa, Philip Jones, S. Marso, J. O’Keefe (2005)
Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.Journal of the American College of Cardiology, 46 5
H. Smulyan, M. Safar (2000)
The Diastolic Blood Pressure in Systolic HypertensionAnnals of Internal Medicine, 132
(2003)
Cardiology guidelines for the management of arterial hypertensionJ Hypertens, 21
U. Brewster, M. Perazella, J. Setaro (2003)
The Renin‐Angiotensin‐Aldosterone System: Cardiorenal Effects and Implications for Renal and Cardiovascular Disease StatesThe American Journal of the Medical Sciences, 326
H. Perry, J. Miller, Jane Fornoff, Jackson Baty, M. Sambhi, G. Rutan, D. Moskowitz, S. Carmody (1995)
Early predictors of 15-year end-stage renal disease in hypertensive patients.Hypertension, 25 4 Pt 1
Morris Brown, J. Cruickshank, A. Dominiczak, G. MacGregor, N. Poulter, G. Russell, S. Thom, B. Williams (2003)
Better blood pressure control: how to combine drugsJournal of Human Hypertension, 17
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ CollaborationLancet, 356
E. Gillespie, C. White, Michael Kardas, M. Lindberg, C. Coleman (2005)
The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.Diabetes care, 28 9
R. Sherwin, Robert Anderson, J. Buse, M. Chin, D. Eddy, J. Fradkin, T. Ganiats, H. Ginsberg, R. Kahn, Robin Nwankwo, M. Rewers, L. Schlessinger, M. Stern, F. Vinicor, B. Zinman (2004)
Prevention or delay of type 2 diabetes.Diabetes care, 27 Suppl 1
D. Beevers (2005)
The end of β blockers for uncomplicated hypertension?The Lancet, 366
R. Caterina, P. Libby, Hai-bing Peng, V. Thannickal, T. Rajavashisth, M. Gimbrone, W. Shin, J. Liao (1995)
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.The Journal of clinical investigation, 96 1
K. Jamerson, V. Dequattro (1996)
The impact of ethnicity on response to antihypertensive therapy.The American journal of medicine, 101 3A
B. Neal (2001)
The Blood Pressure Lowering Treatment Trialists' Collaboration
S. Chrysant, M. Weber, Antonia Wang, D. Hinman (2004)
Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.American journal of hypertension, 17 3
E. O'Brien, J. Barton, J. Nussberger, D. Mulcahy, C. Jensen, P. Dicker, A. Stanton (2007)
Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor BlockerHypertension, 49
J. Cohn, G. Tognoni (2001)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.The New England journal of medicine, 345 23
C. Furberg, J. Wright, B. Davis, J. Cutler, M. Alderman, H. Black, W. Cushman, R. Grimm, L. Haywood, F. Leenen, S. Oparil, J. Probstfield, P. Whelton, C. Nwachuku, D. Gordon, M. Proschan, Paula Einhom, C. Ford, L. Piller, I. Dunn, D. Goff, S. Pressel, Judy Bettencourt, Barbara DeLeon, Lara Simpson, J. Blanton, T. Geraci, Sandra Walsh, C. Nelson, Mahboob Rahman, Anne Juratovac, R. Pospíšil, L. Carroll, Sheila Sullivan, J. Russo, G. Barone, Rudy Christian, S. Feldman, T. Lucente, D. Calhoun, Kimo Jenkins, Peggy McDowell, Janice Johnson, C. Kingry, J. Alzate, K. Margolis, Leslie Holland-Klemme, B. Jaeger, J. Williamson, G. Louis, Pamela Ragusa, A. Williard, R. Ferguson, J. Tanner, J. Eckfeldt, R. Crow, J. Pelosi (2002)
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA, 288 23
N. Luca, J. Mallion, M. O'Rourke, E. O’Brien, K. Rahn, B. Trimarco, R. Romero, P. Leeuw, G. Hitzenberger, E. Battegay, D. Duprez, P. Sever, M. Safar (2004)
Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study.American journal of hypertension, 17 8
S. Bangalore, G. Kamalakkannan, S. Parkar, F. Messerli (2007)
Fixed-dose combinations improve medication compliance: a meta-analysis.The American journal of medicine, 120 8
S. Halimi (2005)
Primary cardiorenal prevention in patients with type-2 diabetesThe Roadmap study [in French]. Presse Med, 34
K. Adalet, H. Oflaz, A. Sezer, K. Büyüköztürk (2001)
Efficacy and Tolerability of Fixed, Low-Dose Combination Therapy with Verapamil Sustained- Release and Trandolapril in Patients with Mild to Severe Essential Hypertension Uncontrolled by Monotherapy: An Open-Label, Multicenter TrialCurrent Therapeutic Research-clinical and Experimental, 62
I. Hajjar, T. Kotchen (2003)
Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.JAMA, 290 2
W. Elliott (1996)
Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjectsClinical Pharmacology & Therapeutics, 60
R. Touyz, F. Tabet, E. Schiffrin (2003)
Redox‐dependent signalling by angiotensin II and vascular remodelling in hypertensionClinical and Experimental Pharmacology and Physiology, 30
R. Fogari, A. Zoppi, P. Lusardi, A. Mugellini, P. Preti, M. Motolese (1997)
Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24-hour noninvasive ambulatory blood pressure monitoring.Journal of cardiovascular pharmacology, 30 2
M. Karpha, G. Lip (2006)
The pathophysiology of target organ damage in hypertension.Minerva cardioangiologica, 54 4
H. Haller, G. Viberti, A. Mimran, G. Remuzzi, A. Rabelink, E. Ritz, L. Rump, L. Ruilope, S. Katayamá, S. Ito, J. Izzo, A. Januszewicz (2006)
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJournal of Hypertension, 24
B. Dahlöf, R. Devereux, S. Kjeldsen, S. Julius, G. Beevers, U. Faire, F. Fyhrquist, H. Ibsen, Krister Kristiansson, O. Lederballe‐Pedersen, L. Lindholm, M. Nieminen, P. Omvik, S. Oparil, H. Wedel (2002)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 359
U. Garg, A. Hassid (1989)
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.The Journal of clinical investigation, 83 5
E. Braunwald, M. Domanski, S. Fowler, N. Geller, B. Gersh, J. Hsia, M. Pfeffer, M. Rice, Y. Rosenberg, J. Rouleau (2004)
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.The New England journal of medicine, 351 20
P. Weidmann, M. Courten, P. Ferrari (1992)
Effect of diuretics on the plasma lipid profile.European heart journal, 13 Suppl G
D. Duprez (2006)
Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical reviewJournal of Hypertension, 24
J. Pool, P. Kaihlanen, G. Lewis, D. Ginsberg, S. Oparil, R. Glazer, F. Messerli (2001)
Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril aloneJournal of Human Hypertension, 15
S. Kjeldsen, S. Kjeldsen, S. Julius, G. Mancia, G. Mcinnes, T. Hua, M. Weber, A. Coca, S. Ekman, X. Girerd, K. Jamerson, P. Larochelle, T. MacDonald, R. Schmieder, M. Schork, Pelle Stolt, R. Viskoper, J. Widimský, A. Zanchetti (2006)
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trialJournal of Hypertension, 24
G. Bakris (1998)
The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium.American journal of hypertension, 11 10
J. Whitworth (2003)
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertensionJournal of Hypertension, 21
S. Aksöyek, N. Özer, K. Aytemir, S. Kes (2001)
VERAPAMIL SR AND TRANDOLAPRIL COMBINATION THERAPY IS SAFE AND EFFECTIVE IN HYPERTENSIVE PATIENTS WITH METABOLIC DISORDERSInternational Journal of Clinical Practice, 55
J. Laragh, R. Letcher, T. Pickering (1979)
Renin profiling for diagnosis and treatment of hypertension.JAMA, 241 2
Hypertension is a multifactorial disorder leading to pathophysiologic changes in target organs over time through diverse mechanisms. In addition, hypertension frequently resists control with monotherapy, necessitating combination therapy with two or more antihypertensive agents. Many currently available fixed-dose antihypertensive combinations combine drugs with different, but complementary, mechanisms of action to improve overall efficacy and tolerability. In addition, it is possible to select drug combinations whereby one drug offsets the negative effects of the other drug. Fixed-dose antihypertensive combinations may provide significant advantages over high-dose monotherapy, such as improved BP-lowering efficacy, reduced adverse event frequency, improved patient compliance, potentially lower treatment costs, and shorter time to BP control. Combination therapy has been recommended as potential first-line therapy in recent consensus guideline statements, especially for higher-risk patients, such as those with stage 2 hypertension. The combination of a renin-angiotensin-aldosterone system-targeting agent, such as an ACE inhibitor or angiotensin II receptor antagonist (ARB), and a diuretic or calcium channel antagonist appears to provide synergy with regard to BP lowering. In addition, ACE inhibitors and ARBs have demonstrated beneficial effects beyond BP reduction, reducing cardiovascular morbidity and mortality, inhibiting development and progression of type 2 diabetes mellitus and the progression of renal disease. Preliminary studies of fixed-dose combinations have shown reductions in left ventricular hypertrophy and improvements in markers of renal function. Additional studies currently underway will compare the effects of available fixed-dose combinations on cardiovascular morbidity and mortality, and markers of renal dysfunction.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.